| Original language | English (US) |
|---|---|
| Pages (from-to) | 553-556.e3 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 135 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2015 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis. / Harden, Jamie L.; Johnson-Huang, Leanne M.; Chamian, Maria Francesca; Lee, Edmund; Pearce, Tillman; Leonardi, Craig L.; Haider, Asifa; Lowes, Michelle A.; Krueger, James G.
In: Journal of Allergy and Clinical Immunology, Vol. 135, No. 2, 01.02.2015, p. 553-556.e3.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis
AU - Harden, Jamie L.
AU - Johnson-Huang, Leanne M.
AU - Chamian, Maria Francesca
AU - Lee, Edmund
AU - Pearce, Tillman
AU - Leonardi, Craig L.
AU - Haider, Asifa
AU - Lowes, Michelle A.
AU - Krueger, James G.
N1 - Funding Information: Disclosure of potential conflict of interest: J. L. Harden and M. A. Lowes have received research support from the National Institutes of Health / National Institute of Arthritis, Musculoskeletal and Skin Diseases (grant no. 1R01AR060222). L. M. Johnson-Huang has received research support from the Linda and Leonard Berkowitz Foundation . M. F. Chamian is employed at a private dermatological practice. T. Pearce is employed by PDF Biopharma and has received stock options as part of his compensation. C. L. Leonardi has received a fee for service as an investigator for PDL, Addvie, Amgen, Anacor, Celgene, Galderma, Janssen, Maruho, Merck, Novartis, Eli Lilly, Leo, Pfizer, Stiefel, and Tolmar; has consultant arrangements with Abbvie, Amgen, Dermira, Eli Lilly, Leo Pharmaceuticals, Pfizer, Sandoz, and UCB; and has received payment for lectures from Abbvie. J. G. Krueger has received research support, consulting fees, and provision of drug for the study from Protein Design Laboratory ; has consultant arrangements with Abbvie, Akros, Amgen, Astellas, Boehringer, Biogen-Idec, Janssen, Dermira, Eli Lilly, Genzyme-Sanofi, Leo Pharmaceutical, Merck, Novartis, and Pfizer; and has received research support from Akros , Amgen , Astellas , Boehringer , Biogen Idec , Centocor / Janssen , Dermira , Lilly , Genzyme-Sanofi , Merck , Novartis , and Pfizer . The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: M.A.L. and J.L.H. were supported by the National Institutes of Health (grant no. 1R01AR060222 ). L.M.J.-H. was supported by the Linda and Leonard Berkowitz Postdoctoral Fellowship .
PY - 2015/2/1
Y1 - 2015/2/1
UR - http://www.scopus.com/inward/record.url?scp=84922435198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922435198&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2014.05.046
DO - 10.1016/j.jaci.2014.05.046
M3 - Article
C2 - 25085340
AN - SCOPUS:84922435198
VL - 135
SP - 553-556.e3
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 2
ER -